Fresenius Kabi Issues Nationwide Recall of Tyenne (tocilizumab-aazg) Injection 400 mg/20 mL Vials Due to Presence of Glass Particles

RegulatoryTyenneNegative

AI Analysis

Summary

Fresenius Kabi issued a nationwide recall of one lot of Tyenne (tocilizumab-aazg) 400 mg/20 mL injection vials due to the presence of glass particles. The recall was announced on August 10, 2026.

Outcome Details

Nationwide recall of one lot due to presence of glass particles

Importance:5/10

Sentiment:

-0.80

product recallsafety issueglass particlesTyennetocilizumab

Related Companies

$FMCQF

Read the original article

Published by Drugs.com FDA MedWatch Alerts on August 10, 2026 9:23 AM

Read Original